Covid-19 Vaccine: Chinese Sinovac shot seen as highly effective in real world study
Skip to main content
  • Home
  • Economy
  • Stocks
  • Analysis
  • World+Biz
  • Sports
  • Features
  • Epaper
  • More
    • Subscribe
    • COVID-19
    • Bangladesh
    • Splash
    • Videos
    • Games
    • Long Read
    • Infograph
    • Interviews
    • Offbeat
    • Thoughts
    • Podcast
    • Quiz
    • Tech
    • Archive
    • Trial By Trivia
    • Magazine
    • Supplement
  • বাংলা
The Business Standard

Thursday
July 07, 2022

Sign In
Subscribe
  • Home
  • Economy
  • Stocks
  • Analysis
  • World+Biz
  • Sports
  • Features
  • Epaper
  • More
    • Subscribe
    • COVID-19
    • Bangladesh
    • Splash
    • Videos
    • Games
    • Long Read
    • Infograph
    • Interviews
    • Offbeat
    • Thoughts
    • Podcast
    • Quiz
    • Tech
    • Archive
    • Trial By Trivia
    • Magazine
    • Supplement
  • বাংলা
THURSDAY, JULY 07, 2022
Chinese Sinovac shot seen as highly effective in real world study

Coronavirus chronicle

TBS Report
12 May, 2021, 09:40 am
Last modified: 12 May, 2021, 12:05 pm

Related News

  • China May oil imports from Russia soar to a record, surpass top supplier Saudi
  • 'US lie may hurt Bangladeshi RMG industry as well,' says China envoy
  • Fresh Covid outbreaks put millions under lockdown in China
  • Covid and bust: China's private health system hurt by tough coronavirus controls
  • China-led trade bloc holds promise, with some caveats

Chinese Sinovac shot seen as highly effective in real world study

The data adds to signs out of Brazil that the Sinovac shot is more effective than it proved in the testing phase, which was beset by divergent efficacy rates and questions over data transparency

TBS Report
12 May, 2021, 09:40 am
Last modified: 12 May, 2021, 12:05 pm
FILE PHOTO: An employee holds a vial containing CoronaVac, Sinovac Biotech's vaccine against the coronavirus disease (COVID-19), at Butantan biomedical production center in Sao Paulo, Brazil January 12, 2021. REUTERS/Amanda Perobelli
FILE PHOTO: An employee holds a vial containing CoronaVac, Sinovac Biotech's vaccine against the coronavirus disease (COVID-19), at Butantan biomedical production center in Sao Paulo, Brazil January 12, 2021. REUTERS/Amanda Perobelli

While non-mRNA vaccines are unlikely to be that effective in preventing transmission, the growing body of evidence that Sinovac's shot works is a boon to China's mission of supplying the developing world in a bid to increase its influence and standing. It's also somewhat of a vindication amid criticism that Chinese vaccine developers disclosed less data and were less transparent about severe adverse events compared with western companies.

Sinovac Biotech Ltd.'s vaccine is wiping out Covid-19 among health workers in Indonesia, an encouraging sign for the dozens of developing countries reliant on the controversial Chinese shot, which performed far worse than western vaccines in clinical trials, Bloomberg reported.

Indonesia tracked 25,374 health workers in capital city Jakarta for 28 days after they received their second dose and found that the vaccine protected 100% of them from death and 96% from hospitalization as soon as seven days after, said Health Minister Budi Gunadi Sadikin in an interview on Tuesday. The workers were tracked until late February.

Sadikin also said that 94% of the workers had been protected against infection -- an extraordinary result that goes beyond what was measured in the shot's numerous clinical trials -- though it's unclear if the workers were uniformly screened to detect asymptomatic carriers.

"We see a very, very drastic drop," in hospitalizations and deaths among medical workers, Sadikin said. It's not known what strain of the coronavirus Sinovac's shot worked against in Indonesia, but the country has not flagged any major outbreaks driven by variants of concern.

The data adds to signs out of Brazil that the Sinovac shot is more effective than it proved in the testing phase, which was beset by divergent efficacy rates and questions over data transparency. Results from its biggest Phase III trial in Brazil put the shot known as CoronaVac's efficacy at just above 50%, the lowest among all first-generation Covid vaccines.

A spokesman for Sinovac in Beijing said the company cannot comment on the Indonesian study until it acquires more details.

In a separate interview with Bloomberg Tuesday, Sinovac's chief executive officer Yin Weidong defended the disparity in clinical data around the shot, and said there was growing evidence CoronaVac is performing better when applied in the real world.

But the real-world examples also show that the Sinovac shot's ability to quell outbreaks requires the vast majority of people to be vaccinated, a scenario that developing countries with poor health infrastructure and limited access to shots cannot reach quickly. In the Indonesian health worker study, and another in a Brazilian town of 45,000 people called Serrana, nearly 100% of people studied were fully vaccinated, with serious illness and deaths dropping after they were inoculated.

In contrast, Chile saw a resurgent outbreak after vaccinating over a third of the population of 19 million -- one of the fastest rates in the world, but not fast enough to stop the spread of the aggressive variant sweeping Latin America.

"The earliest group of people vaccinated in Chile are old people. Less than 15 million of doses given to Chile means only 7 million people can get our shots. That equals to only 36% of a population of 19 million," said Yin. "It's normal that the country sees a resurgence of infections as social activities increase among the younger people who are mainly not inoculated."

Among people vaccinated with CoronaVac in Chile, 89% were protected from serious Covid that requires intensive care, said Yin.

The vaccine's protection is likely to vary from place to place due to virus variants, but Sinovac's shot appears to be holding up well against the new mutations of concern, he said.

A key question for all Covid vaccines is whether they can prevent or deter actual transmission of the virus. Yin said Tuesday that Sinovac does not yet know if its shot -- a traditional inactivated vaccine -- can stop or reduce the virus from being contracted in the first place, but the fact it is preventing serious illness and death is more important.

"The results from real-world application and the scientific data we have from clinical trials will allow the world to judge our vaccine comprehensively," said Yin. "We encourage our partners and governments in countries where our vaccine is being used to release such data as soon as possible."

Indonesia was one of the earliest countries to place its bets on a Chinese vaccine. In January, President Joko Widodo became the first major world leader to receive the Sinovac shot in a bid to quell skepticism at home and abroad. Since then, Southeast Asia's largest economy has administered more than 22 million doses, mostly Sinovac, as it seeks to reach herd immunity for its 270-million strong population by year-end.

"The minimum efficacy rate should be above 50%, so beyond that, the best vaccine is the one you can get as soon as possible, as every shot given can prevent deaths," Health Minister Sadikin said. "It isn't only about getting the highest efficacy rate, but inoculating people quickly."

While neighboring Malaysia and Thailand are seeing a resurgence in cases, Indonesia's rate of new infections and deaths has stabilized since a January peak. But with its massive population still mostly unprotected, the upcoming Eid holiday could cause cases to rebound by as much as 60% as people gather with family and travel home despite government restrictions, Sadikin warned.

Helen Petousis-Harris, a vaccinologist at the University of Auckland, said that the ability of vaccines to control a disease can be higher in the real world than when measured in clinical trials.

"In my experience, we often fail to predict the overall impact of vaccines, something that can only be seen in the real world after widespread use," she said. "Reducing the bulk of disease is not only essential to save lives but also to reduce the chances of problematic variants appearing."

The mRNA shot developed by BioNTech SE and Pfizer Inc. has been shown to be over 90% effective in preventing transmission in Israel.

Top News / World+Biz

Sinovac Covid-19 Vaccine / Chinese Sinovac company / china / Chinese vaccine / covid-19 vaccine

Comments

While most comments will be posted if they are on-topic and not abusive, moderation decisions are subjective. Published comments are readers’ own views and The Business Standard does not endorse any of the readers’ comments.

Top Stories

  • BPC looks for $2b as fuel stock depletes fast
    BPC looks for $2b as fuel stock depletes fast
  • Photo: Unicef
    Nearly 10% of global population affected by hunger last year: UN
  • Call money rate hits 5.48% amid rising cash demand ahead of Eid
    Call money rate hits 5.48% amid rising cash demand ahead of Eid

MOST VIEWED

  • A medical worker takes a swab sample at a nucleic acid testing station, following a coronavirus disease (COVID-19) outbreak, in Beijing, China, July 6, 2022. REUTERS/Thomas Peter
    Fresh Covid outbreaks put millions under lockdown in China
  • A medical staff in protective suit works at a nucleic acid testing laboratory of Nanjing First Hospital following a citywide mass testing for the coronavirus disease (COVID-19) in Nanjing, Jiangsu province, China July 24, 2021. cnsphoto via REUTERS/File Photo
    Covid and bust: China's private health system hurt by tough coronavirus controls
  • Illustration: Collected
    Omicron BA.5 most predominant Covid sub-variant in Bangladesh: icddr,b
  • A man helps his son to wear mask at Covid-19 test centre at KSRTC bus stand in Bengaluru.(PTI)
    India records 16,103 new Covid cases, 31 deaths in 24 hours
  • Former North Korean defectors living in South Korea, release balloons containing one dollar banknotes, radios, CDs and leaflets denouncing the North Korean regime, towards the north near the demilitarized zone which separates the two Koreas in Paju, north of Seoul January 15, 2014. REUTERS/Kim Hong-Ji/File Photo
    North Korea blames 'alien things' near border with South for Covid outbreak
  • People wearing protective face masks commute amid concerns over the new coronavirus disease (COVID-19) in Pyongyang, North Korea March 30, 2020, in this photo released by Kyodo. Picture taken March 30, 2020. Mandatory credit Kyodo/via REUTERS
    S Korea says leaflets sent by defectors unlikely to be cause of Covid in N Korea

Related News

  • China May oil imports from Russia soar to a record, surpass top supplier Saudi
  • 'US lie may hurt Bangladeshi RMG industry as well,' says China envoy
  • Fresh Covid outbreaks put millions under lockdown in China
  • Covid and bust: China's private health system hurt by tough coronavirus controls
  • China-led trade bloc holds promise, with some caveats

Features

The sea beach in Kuakata. Photo: Syed Mehedy Hasan

Five places in Southern Bangladesh you could visit via Padma Bridge

16h | Explorer
Genex Infosys Limited is the country's largest call centre with more than 2,000 seats and full-set equipment. Photo: Courtesy

How domestic demand made Genex Infosys a BPO industry leader

17h | Panorama
The OPEC+ group of 23 oil-exporting countries met virtually on Thursday. Photo: Bloomberg

OPEC+ did its job, but don’t expect it to disappear

1d | Panorama
Mirza Abdul Kader Sardar with AK Fazlul Haque, Chief Minister of Bengal, at Haque's reception at the Lion Cinema, Dhaka, 1941. Photo: Collected

Panchayats: Where tradition clings to survival

1d | Panorama

More Videos from TBS

Behind the story of 'Aske Amar Mon Bhalo Nei'

Behind the story of 'Aske Amar Mon Bhalo Nei'

5h | Videos
Is Donbas Putin’s next target?

Is Donbas Putin’s next target?

9h | Videos
Hajj Journey: it took more than one year to complete the Hajj

Hajj Journey: it took more than one year to complete the Hajj

10h | Videos
Photo: TBS

Cristiano Ronaldo looking for a new challenge

15h | Videos

Most Read

1
Photo: Collected
Africa

Uganda discovers gold deposits worth 12 trillion USD

2
TBS Illustration
Education

Universities may launch online classes again after Eid

3
Area-wise load shedding schedule will be announced: PM
Bangladesh

Area-wise load shedding schedule will be announced: PM

4
Padma Bridge opens up investment spree in south
Industry

Padma Bridge opens up investment spree in south

5
Build Dhaka East-West Elevated Expressway, relocate kitchen markets: PM
Bangladesh

Build Dhaka East-West Elevated Expressway, relocate kitchen markets: PM

6
File Photo: BSS
Energy

India pulls out of LoC funding for part of Rooppur power transmission work

EMAIL US
contact@tbsnews.net
FOLLOW US
WHATSAPP
+880 1847416158
The Business Standard
  • About Us
  • Contact us
  • Sitemap
  • Privacy Policy
  • Comment Policy
Copyright © 2022
The Business Standard All rights reserved
Technical Partner: RSI Lab
BENEATH THE SURFACE
A customer checks a knife at a blacksmith’s shop at the capital’s Karwan Bazar. Knives and other Qurbani tools are in huge demand as the country prepares to celebrate Eid-Ul-Azha. Photo: Rajib Dhar

Contact Us

The Business Standard

Main Office -4/A, Eskaton Garden, Dhaka- 1000

Phone: +8801847 416158 - 59

Send Opinion articles to - oped.tbs@gmail.com

For advertisement- sales@tbsnews.net